Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390442 | 0.78 | DPP4 (0.57) | DPP4ALDH1A1KMT2A | |
| SCHEMBL3388719 | 0.75 | DPP4 (0.65) | DPP4 | |
| SCHEMBL8235171 | 0.74 | DPP4 (1.00) | DPP4 | |
| SCHEMBL15180941 | 0.70 | P2RX3 (0.47) | ALDH1A1SMN1; SMN2POLBP2RX3KDM4E | |
| SCHEMBL7819044 | 0.68 | HTT (0.46) | ALOX15ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3911305 | 0.66 | BTK (0.38) | ALDH1A1SMN1; SMN2MEN1KMT2AP2RX3 | |
| SCHEMBL3388746 | 0.65 | DPP4 (0.57) | DPP4KMT2A | |
| SCHEMBL18851466 | 0.64 | NOX4 (0.39) | DPP4ALOX15ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL3391420 | 0.64 | DPP4 (0.60) | DPP4KMT2ACYP3A4 | |
| SCHEMBL8210070 | 0.63 | THRB (0.46) | DPP4ALDH1A1POLBKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1911754-A1 | Dipeptidyl peptidase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | claimed |
| CN-1867560-A | 4-pyrimidone derivatives and their use as peptidylpeptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2006-11-22 | — | — | CN | claimed |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | claimed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | claimed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1911754-B1 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-7790736-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790736-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790736-B2 | Dipeptidyl peptidase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7723344-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723344-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723344-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20050075330-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-04-07 | — | — | US | disclosed |
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050070530-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | SYRRX, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2005016911-A1 | 4-PYRIMIDONE DERIVATIVES AND THEIR USE AS PEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-24 | — | — | WO | disclosed |
| EP-1506967-A1 | Dipeptidyl peptidase inhibitors | Syrrx, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070535-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885ALOX15 3579/4885ALDH1A1 370/4885 |
| US-20050070531-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885ALOX15 3579/4885ALDH1A1 370/4885 |
| US-20050065148-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885ALOX15 3579/4885ALDH1A1 370/4885 |
| US-20050075330-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885ALOX15 3579/4885ALDH1A1 370/4885 |
| US-20050070706-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885ALOX15 3579/4885ALDH1A1 370/4885 |
| US-20050070530-A1 | Dipeptidyl peptidase inhibitors | DPP4, DPP3, DPP7 | DPP4 1/4885ALOX15 3579/4885ALDH1A1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.